Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET.

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in January:

Jounce Therapeutics to Present at Upcoming Investor Conferences in January

Jounce is making an attempt to renovate how we treat cancer by developing novel immunotherapies that could expand these treatments to new patients and tumor types. The company's platform and R&D capabilities are impressive. If all goes well, Jounce could have several blockbuster drugs in their pipeline.

Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in November:

Jounce Therapeutics to Present at Upcoming Investor Conferences in November

Jounce Therapeutics, Inc's. (JNCE) CEO Richard Murray on Q3 2021 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -47.50% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Lags Revenue Estimates

- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 -

Jounce Therapeutics Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results and provide a corporate update before market open on Thursday, November 4, 2021. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. E.T.

Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021

- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts –

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.

Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September:

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q2 2021 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 78.95% and 167.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial results and provide a corporate update before market open on Thursday, August 5, 2021. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00am ET.

Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021

Jounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies.

Jounce Therapeutics: An Under The Radar And Undervalued Biotech

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will participate in a panel discussion at the William Blair's Biotech Focus Conference taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference

- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021-

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

The company gets a regulatory nod that will put $25 million in its pocket.

Why Jounce Therapeutics Bounced Higher Today

Gilead Sciences

The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc (NASDAQ: GILD). JTX-1811, referred to as GS-1811 in Gilead's pipeline, is a monoclonal antibody to deplete immunosuppressive tumor-infiltrating T regulatory cells selectively.

Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president will participate in a fireside chat at the Raymond James Human Health Innovation Conference, taking place virtually on Monday, June 21, 2021 at 12:40 p.m. ET.

Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference

- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas -

Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript

News for Jounce Therapeutics Stock (JNCE)